Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-01-20

AUTHORS

Iacopo Baussano, Joakim Dillner, Fulvio Lazzarato, Guglielmo Ronco, Silvia Franceschi

ABSTRACT

BackgroundThe decrease in human papillomavirus (HPV) vaccine prices may allow upscale already started vaccination programmes but the advantages of different options are unclear.MethodsUsing a mathematical model of HPV16 and 18 transmission and data on vaccination coverage from Italy, we compared 3 options to upscale an already started programme targeting 11-year old girls (coverage 65%): a) coverage improvement (from 65% to 90%); b) addition of 11-year-old boys (coverage 65%); or c) 1-year catch-up of older girls (coverage 50%).ResultsThe reduction of cervical HPV16/18 infection as compared to no vaccination (i.e. effectiveness against HPV16/18) increased from 76% to 98% with coverage improvement in girls and to 90% with the addition of boys. With higher coverage in girls, HPV16/18 infection cumulative probability by age 35 decreased from 25% to 8% with a 38% increase in vaccine number. The addition of boys decreased the cumulative probability to 18% with a 100% increase in the number of vaccinees. For any coverage in girls, the number of vaccinees to prevent 1 woman from being infected by HPV16/18 by age 35 was 1.5, whereas it was 2.7 for the addition of boys. Catch-up of older girls only moved forward the vaccination effectiveness by 2–5 years.ConclusionsIncreasing vaccination coverage among girls is the most effective option for decreasing HPV16/18. If not achievable, vaccinating boys is justifiable if vaccine cost has at least halved, because this option would almost double the number of vaccinees. More... »

PAGES

4

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1750-9378-9-4

DOI

http://dx.doi.org/10.1186/1750-9378-9-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1053142134

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24438317


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon cedex 08, France", 
          "id": "http://www.grid.ac/institutes/grid.17703.32", 
          "name": [
            "International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon cedex 08, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baussano", 
        "givenName": "Iacopo", 
        "id": "sg:person.01017470253.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017470253.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Karolinska Institutet, Nobels v\u00e4g 12A, 17177, Stockholm, Sweden", 
          "id": "http://www.grid.ac/institutes/grid.4714.6", 
          "name": [
            "Karolinska Institutet, Nobels v\u00e4g 12A, 17177, Stockholm, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dillner", 
        "givenName": "Joakim", 
        "id": "sg:person.01254603055.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254603055.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Sciences, Unit of Cancer Epidemiology, University of Turin, Via Santena 7, 10126, Turin, Italy", 
          "id": "http://www.grid.ac/institutes/grid.7605.4", 
          "name": [
            "Department of Medical Sciences, Unit of Cancer Epidemiology, University of Turin, Via Santena 7, 10126, Turin, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lazzarato", 
        "givenName": "Fulvio", 
        "id": "sg:person.0655244536.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655244536.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre for Cancer Prevention, Via San Francesco da Paola 31, 10123, Turin, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Centre for Cancer Prevention, Via San Francesco da Paola 31, 10123, Turin, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ronco", 
        "givenName": "Guglielmo", 
        "id": "sg:person.01206540103.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01206540103.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon cedex 08, France", 
          "id": "http://www.grid.ac/institutes/grid.17703.32", 
          "name": [
            "International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon cedex 08, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Franceschi", 
        "givenName": "Silvia", 
        "id": "sg:person.01074225776.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074225776.01"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/1742-4682-5-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027710781", 
          "https://doi.org/10.1186/1742-4682-5-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6603575", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030162506", 
          "https://doi.org/10.1038/sj.bjc.6603575"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-01-20", 
    "datePublishedReg": "2014-01-20", 
    "description": "BackgroundThe decrease in human papillomavirus (HPV) vaccine prices may allow upscale already started vaccination programmes but the advantages of different options are unclear.MethodsUsing a mathematical model of HPV16 and 18 transmission and data on vaccination coverage from Italy, we compared 3 options to upscale an already started programme targeting 11-year old girls (coverage 65%): a) coverage improvement (from 65% to 90%); b) addition of 11-year-old boys (coverage 65%); or c) 1-year catch-up of older girls (coverage 50%).ResultsThe reduction of cervical HPV16/18 infection as compared to no vaccination (i.e. effectiveness against HPV16/18) increased from 76% to 98% with coverage improvement in girls and to 90% with the addition of boys. With higher coverage in girls, HPV16/18 infection cumulative probability by age 35 decreased from 25% to 8% with a 38% increase in vaccine number. The addition of boys decreased the cumulative probability to 18% with a 100% increase in the number of vaccinees. For any coverage in girls, the number of vaccinees to prevent 1 woman from being infected by HPV16/18 by age 35 was 1.5, whereas it was 2.7 for the addition of boys. Catch-up of older girls only moved forward the vaccination effectiveness by 2\u20135\u00a0years.ConclusionsIncreasing vaccination coverage among girls is the most effective option for decreasing HPV16/18. If not achievable, vaccinating boys is justifiable if vaccine cost has at least halved, because this option would almost double the number of vaccinees.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/1750-9378-9-4", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.3790281", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.3795835", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1037008", 
        "issn": [
          "1750-9378"
        ], 
        "name": "Infectious Agents and Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "9"
      }
    ], 
    "keywords": [
      "number of vaccinees", 
      "old girl", 
      "vaccination coverage", 
      "age 35", 
      "human papillomavirus vaccination", 
      "cumulative probability", 
      "HPV16/18 infection", 
      "papillomavirus vaccination", 
      "vaccination program", 
      "vaccination effectiveness", 
      "vaccine cost", 
      "high-income countries", 
      "vaccine price", 
      "vaccinees", 
      "effective option", 
      "HPV16/18", 
      "vaccination", 
      "boys", 
      "girls", 
      "options", 
      "HPV16", 
      "infection", 
      "women", 
      "transmission model", 
      "increase", 
      "improvement", 
      "addition", 
      "years", 
      "program", 
      "number", 
      "assessment", 
      "decrease", 
      "coverage", 
      "reduction", 
      "transmission", 
      "different options", 
      "coverage improvement", 
      "high coverage", 
      "data", 
      "effectiveness", 
      "countries", 
      "Italy", 
      "probability", 
      "model", 
      "cost", 
      "advantages", 
      "upscale", 
      "impact assessment", 
      "mathematical model", 
      "prices"
    ], 
    "name": "Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model", 
    "pagination": "4", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1053142134"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1750-9378-9-4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24438317"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1750-9378-9-4", 
      "https://app.dimensions.ai/details/publication/pub.1053142134"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:40", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_643.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/1750-9378-9-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1750-9378-9-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1750-9378-9-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1750-9378-9-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1750-9378-9-4'


 

This table displays all metadata directly associated to this object as RDF triples.

159 TRIPLES      21 PREDICATES      77 URIs      67 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1750-9378-9-4 schema:about anzsrc-for:11
2 anzsrc-for:1117
3 schema:author Nc76f00e923e9459c9c549c634b4c1099
4 schema:citation sg:pub.10.1038/sj.bjc.6603575
5 sg:pub.10.1186/1742-4682-5-4
6 schema:datePublished 2014-01-20
7 schema:datePublishedReg 2014-01-20
8 schema:description BackgroundThe decrease in human papillomavirus (HPV) vaccine prices may allow upscale already started vaccination programmes but the advantages of different options are unclear.MethodsUsing a mathematical model of HPV16 and 18 transmission and data on vaccination coverage from Italy, we compared 3 options to upscale an already started programme targeting 11-year old girls (coverage 65%): a) coverage improvement (from 65% to 90%); b) addition of 11-year-old boys (coverage 65%); or c) 1-year catch-up of older girls (coverage 50%).ResultsThe reduction of cervical HPV16/18 infection as compared to no vaccination (i.e. effectiveness against HPV16/18) increased from 76% to 98% with coverage improvement in girls and to 90% with the addition of boys. With higher coverage in girls, HPV16/18 infection cumulative probability by age 35 decreased from 25% to 8% with a 38% increase in vaccine number. The addition of boys decreased the cumulative probability to 18% with a 100% increase in the number of vaccinees. For any coverage in girls, the number of vaccinees to prevent 1 woman from being infected by HPV16/18 by age 35 was 1.5, whereas it was 2.7 for the addition of boys. Catch-up of older girls only moved forward the vaccination effectiveness by 2–5 years.ConclusionsIncreasing vaccination coverage among girls is the most effective option for decreasing HPV16/18. If not achievable, vaccinating boys is justifiable if vaccine cost has at least halved, because this option would almost double the number of vaccinees.
9 schema:genre article
10 schema:isAccessibleForFree true
11 schema:isPartOf N2f271fb6436d47d09f9907da432d37bb
12 N860b8d1225754d8290f623ac7a960154
13 sg:journal.1037008
14 schema:keywords HPV16
15 HPV16/18
16 HPV16/18 infection
17 Italy
18 addition
19 advantages
20 age 35
21 assessment
22 boys
23 cost
24 countries
25 coverage
26 coverage improvement
27 cumulative probability
28 data
29 decrease
30 different options
31 effective option
32 effectiveness
33 girls
34 high coverage
35 high-income countries
36 human papillomavirus vaccination
37 impact assessment
38 improvement
39 increase
40 infection
41 mathematical model
42 model
43 number
44 number of vaccinees
45 old girl
46 options
47 papillomavirus vaccination
48 prices
49 probability
50 program
51 reduction
52 transmission
53 transmission model
54 upscale
55 vaccination
56 vaccination coverage
57 vaccination effectiveness
58 vaccination program
59 vaccine cost
60 vaccine price
61 vaccinees
62 women
63 years
64 schema:name Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model
65 schema:pagination 4
66 schema:productId N28350878cb2348668b075ec8f6c9ec03
67 N9f112991aaca42909aa7664ecd016701
68 Nb7a04fb1f1b944e09e39aa3077bc70ed
69 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053142134
70 https://doi.org/10.1186/1750-9378-9-4
71 schema:sdDatePublished 2022-10-01T06:40
72 schema:sdLicense https://scigraph.springernature.com/explorer/license/
73 schema:sdPublisher N353612d617674be9a720d6a5bc178278
74 schema:url https://doi.org/10.1186/1750-9378-9-4
75 sgo:license sg:explorer/license/
76 sgo:sdDataset articles
77 rdf:type schema:ScholarlyArticle
78 N1a1dd1e5b08c4cc8a79f472815112c73 rdf:first sg:person.01206540103.18
79 rdf:rest N44e9a4f2f35c4875b11b58aea56136e4
80 N28350878cb2348668b075ec8f6c9ec03 schema:name doi
81 schema:value 10.1186/1750-9378-9-4
82 rdf:type schema:PropertyValue
83 N2f271fb6436d47d09f9907da432d37bb schema:issueNumber 1
84 rdf:type schema:PublicationIssue
85 N353612d617674be9a720d6a5bc178278 schema:name Springer Nature - SN SciGraph project
86 rdf:type schema:Organization
87 N44e9a4f2f35c4875b11b58aea56136e4 rdf:first sg:person.01074225776.01
88 rdf:rest rdf:nil
89 N860b8d1225754d8290f623ac7a960154 schema:volumeNumber 9
90 rdf:type schema:PublicationVolume
91 N9f112991aaca42909aa7664ecd016701 schema:name pubmed_id
92 schema:value 24438317
93 rdf:type schema:PropertyValue
94 Nafa62afb7f7e4fe9a10f2137c703093b rdf:first sg:person.01254603055.20
95 rdf:rest Nbd81f4e5d18644269b205e658fdf2a1c
96 Nb7a04fb1f1b944e09e39aa3077bc70ed schema:name dimensions_id
97 schema:value pub.1053142134
98 rdf:type schema:PropertyValue
99 Nbd81f4e5d18644269b205e658fdf2a1c rdf:first sg:person.0655244536.42
100 rdf:rest N1a1dd1e5b08c4cc8a79f472815112c73
101 Nc76f00e923e9459c9c549c634b4c1099 rdf:first sg:person.01017470253.82
102 rdf:rest Nafa62afb7f7e4fe9a10f2137c703093b
103 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
104 schema:name Medical and Health Sciences
105 rdf:type schema:DefinedTerm
106 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
107 schema:name Public Health and Health Services
108 rdf:type schema:DefinedTerm
109 sg:grant.3790281 http://pending.schema.org/fundedItem sg:pub.10.1186/1750-9378-9-4
110 rdf:type schema:MonetaryGrant
111 sg:grant.3795835 http://pending.schema.org/fundedItem sg:pub.10.1186/1750-9378-9-4
112 rdf:type schema:MonetaryGrant
113 sg:journal.1037008 schema:issn 1750-9378
114 schema:name Infectious Agents and Cancer
115 schema:publisher Springer Nature
116 rdf:type schema:Periodical
117 sg:person.01017470253.82 schema:affiliation grid-institutes:grid.17703.32
118 schema:familyName Baussano
119 schema:givenName Iacopo
120 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017470253.82
121 rdf:type schema:Person
122 sg:person.01074225776.01 schema:affiliation grid-institutes:grid.17703.32
123 schema:familyName Franceschi
124 schema:givenName Silvia
125 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074225776.01
126 rdf:type schema:Person
127 sg:person.01206540103.18 schema:affiliation grid-institutes:None
128 schema:familyName Ronco
129 schema:givenName Guglielmo
130 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01206540103.18
131 rdf:type schema:Person
132 sg:person.01254603055.20 schema:affiliation grid-institutes:grid.4714.6
133 schema:familyName Dillner
134 schema:givenName Joakim
135 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254603055.20
136 rdf:type schema:Person
137 sg:person.0655244536.42 schema:affiliation grid-institutes:grid.7605.4
138 schema:familyName Lazzarato
139 schema:givenName Fulvio
140 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655244536.42
141 rdf:type schema:Person
142 sg:pub.10.1038/sj.bjc.6603575 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030162506
143 https://doi.org/10.1038/sj.bjc.6603575
144 rdf:type schema:CreativeWork
145 sg:pub.10.1186/1742-4682-5-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027710781
146 https://doi.org/10.1186/1742-4682-5-4
147 rdf:type schema:CreativeWork
148 grid-institutes:None schema:alternateName Centre for Cancer Prevention, Via San Francesco da Paola 31, 10123, Turin, Italy
149 schema:name Centre for Cancer Prevention, Via San Francesco da Paola 31, 10123, Turin, Italy
150 rdf:type schema:Organization
151 grid-institutes:grid.17703.32 schema:alternateName International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon cedex 08, France
152 schema:name International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon cedex 08, France
153 rdf:type schema:Organization
154 grid-institutes:grid.4714.6 schema:alternateName Karolinska Institutet, Nobels väg 12A, 17177, Stockholm, Sweden
155 schema:name Karolinska Institutet, Nobels väg 12A, 17177, Stockholm, Sweden
156 rdf:type schema:Organization
157 grid-institutes:grid.7605.4 schema:alternateName Department of Medical Sciences, Unit of Cancer Epidemiology, University of Turin, Via Santena 7, 10126, Turin, Italy
158 schema:name Department of Medical Sciences, Unit of Cancer Epidemiology, University of Turin, Via Santena 7, 10126, Turin, Italy
159 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...